Ferrocene-bridged bicyclic-[2.2.1]-heptyl diene compound
A ferrocene and compound technology, applied in the field of ferrocene-oxo bridge bicyclo-[2.2.1]-heptene compounds, can solve the problems of increasing the risk of endometrial cancer due to drug resistance
Active Publication Date: 2015-12-02
2 Cites 4 Cited by
AI-Extracted Technical Summary
Problems solved by technology
The invention discloses a ferrocene-bridged bicyclic-[2.2.1]-heptyl diene compound that contains N-hydroxy-(i)N-benzene succinic amide or a similar structure. 3-(4-hydroxyphenyl)-4-suberic nonacylanilino-furan or similar analogs and a ferrocene vinyl sulfonate derivative are used as raw materials, and a solvent and a catalyst are not needed; the raw materials are reacted for 3 hours at 90 DEG C through one step to obtain a ferrocene-bridged bicyclic-[2.2.1]-heptyl diene compound that contains a suberic nonacylanilino group. According to an in vitro experiment, compared with a current anti-cancer drug Tamoxifen, the novel ferrocene-bridged bicyclic-[2.2.1]-heptyl diene compound has stronger inhibitory activity on hormone-dependent breast cancer MCF-7 cells and non-hormone-dependent breast cancer MDA-MB-231 cells, and has no toxicity on normal VERO cells while the current anti-cancer drug Tamoxifen has toxicity on normal VERO cells.
Organic active ingredientsAntineoplastic agents +1
BenzenePerylene derivatives +23
- Experimental program(10)
Description & Claims & Application Information
We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.